SUMMARY
We have shown that subanaesthetic concentrations of isoflurane (0.1-0.6%) provide a useful alternative technique for sedation of patients undergoing ventilation in the ITU [1] . Many critically ill patients may be expected to be receiving drug treatment which could result in hepatic enzyme induction. The metabolism of isoflurane to inorganic fluoride (F~) and its renal effects in these patients were therefore studied.
PATIENTS AND METHODS
We studied 60 patients who required mechanical ventilation in the ITU. Patients were excluded if they were pregnant, had head injury or were in coma, were already under an established scheme of sedation, had a history of allergic response to morphine or benzodiazepines, were grossly obese or had uncontrolled haemorrhage. The study was approved by the Bristol and Weston District Ethics Committee. Informed consent for participation was obtained either from the patient or from the next of kin. Patients were allocated randomly to receive either 0.1-0.6% isoflurane in an air-oxygen mixture or a continuous i.v. infusion of midazolam 0.01-0.2 mg kg" 1 h" 1 for sedation. In those patients who received isoflurane for sedation, end-tidal concentrations of the agent were measured with a Siemens Gas Monitor and MAC hours of isoflurane calculated. By definition, MAC is not directly applicable to sedated patients and the end-tidal concentrations and duration of sedation were used to calculate the "volume per cent hours " of isoflurane in each patient. The dose of sedative was adjusted to maintain a desired degree of sedation for as long as possible. The trial sedative was stopped either when the patient was judged ready for weaning from ventilatory support, or at 24 h (whichever was earlier). If sedation was required beyond 24 h, an alternative scheme of sedation was substituted.
Arterial blood samples were collected for measurement of plasma F~ at baseline, at the end of the period of trial sedation, and at 24 h after discontinuing the trial sedative. It was realized •Present address for correspondence: University Department of Anaesthesia, Queen Elizabeth Hospital, Birmingham B15 2TH.
later that this frequency of sampling was inadequate in those patients receiving isofiurane sedation, and additional blood samples were taken at 4 and 12 h after discontinuing the trial sedative in subsequent patients who received isoflurane for sedation. In five of these patients further samples were taken also at 48 h after stopping isoflurane sedation.
The plasma was separated, frozen and, subsequently, ionic F~ concentrations determined by direct ion-selective potentiometry using a fluoride-glass pH electrode system [2, 3] . Interassay coefficients of variation were 2.2% and 1.3% at mean plasma F~ concentrations of 2.0 ^mol litre" 1 and 30 \imol litre" 1 , respectively. The lower limit for fluoride determination was 0.1 (xmol litre" 1 , with linearity from the lower limit of detection to 90 nmol litre" 1 (linear correlation coefficient, r = 0.999). Care was taken to avoid fluoride contamination. Arterial blood samples were taken also at baseline, at the end of the period of trial sedation and 24 h after sedation for measurement of serum electrolytes, urea and creatinine concentrations. Hourly urine output was recorded.
Nominal data were analysed by the Chi square test; for other data which could be assumed to be distributed normally, paired and unpaired t tests were used to compare means within and between groups, respectively; otherwise, the MannWhitney U test was used.
RESULTS
Of the 60 patients studied, results from 14 patients were incomplete either because they died during the study or because they had to return to theatre before blood sampling was completed. Results from the remaining 46 patients were analysed. Table I shows the details of these patients, 26 of whom received isoflurane and 20 midazolam. Twenty-one patients sedated with isoflurane and 16 of those sedated with midazolam had received a volatile agent during surgery before entry to the study. The interval between the end of the anaesthetic and start of the study ranged from 45 min to 3 h in these patients. The two groups of patients were comparable in sex distribution, age, weight, APACHE II score and duration of study.
Patients who received isoflurane for sedation showed a continuous increase in plasma F", whereas there was no significant change in plasma F" in those patients who received midazolam ( fig.  1 ). More frequent blood samplings and measurements of plasma F" in those later patients who received isoflurane revealed that maximum plasma F" (13.57 |xmol litre" 1 ) occurred 12 h after discontinuing isoflurane ( fig. 2) . The mean (range) dose of isoflurane used for sedation was 2.84 (1.14-6.38) MAC hours or 2.99 (1.2-6.7) vol% hours. In five of these patients, blood samples taken 48 h after discontinuation of isoflurane showed that, although plasma F" had declined considerably, they were still increased above normal values ( fig. 2 ).
There were no significant differences in serum sodium, potassium, chloride and bicarbonate concentrations from baseline values in the two groups (table II) . Serum urea and creatinine concentrations measured at the end of the study period and 24 h later were higher than baseline values in the two groups of patients, but there were no differences in urea or creatinine concentrations between the isoflurane and midazolam groups during the study period. Hourly urine outputs in both groups were within normal limits, and there was no difference in mean (SEM) hourly urine output during the study: 73.4 (7.5) ml h" 1 compared with 79.6 (9.3) ml h" 1 , respectively.
DISCUSSION
Metabolism of methoxyflurane to F~ was shown to result in dose-related, polyuric renal insufficiency in man [4] . As a result of these studies, methoxyflurane was withdrawn from human use. The extent of enflurane biotransformation to F" is insufficient to result in clinically significant nephrotoxicity [5] , even in patients with pre-existing renal insufficiency [6] . As only 0.2% of an absorbed dose of isoflurane is biotransformed [7] , F" nephrotoxicity appears unlikely. Studies in man have shown that, following exposure to 3.1 MAC hours of isoflurane during surgical procedures lasting 2-7.5 h, serum F~ increased to mean peak values of about 4.4 umol litre" 1 from preoperative baseline values of 2.2 umol litre" 1 [8] . Slightly greater peak serum F" concentrations (6.5 umol litre" 1 ) were reported in morbidly obese patients exposed to 2.5 MAC hours of isoflurane [9] . We have used subanaesthetic concentrations of isoflurane (0.1-0.6 %) over much longer periods (mean duration 18.2 h). In our group of patients undergoing ventilation the metabolism of isoflurane may have been increased or altered by factors such as changes in hepatic blood flow, hypoxaemia, drugs (especially enzyme inducing drugs), genetic variation and concurrent illnesses. Compared with the above studies we found a greater mean maximum plasma fluoride concentration (13.57 umol litre" 1 ) following sedation with a mean dose of 2.84 MAC hours isoflurane (2.99 vol% hours). However, this plasma F~ is still far below that (50 umol litre" 1 ) which has been reported to cause subclinical nephrotoxicity [10] . The majority of our patients were postoperative surgical patients, many of whom had received an anaesthetic with a volatile agent before entry to the study. We were unable to determine the effect of this exposure on the maximum increase in plasma F". This maximum occurred 12 h after stopping isoflurane, later than the 6 h after the end of an isoflurane anaesthetic reported by Mazze, Cousins and Barr [8] , but similar to that seen in morbidly obese patients [9] . Plasma F" in our patients were still increased 48 h after stopping isoflurane sedation. We were unable to demonstrate any relationship between MAC hours or vol% hours of isoflurane used and maximum plasma F~.
Hourly urine output in both groups was similar and not excessive. However, urinary concentrating ability, the most sensitive indicator of Fñ ephropathy, was not measured. Both groups demonstrated increases in serum urea and creatinine concentrations from baseline values following isoflurane or midazolam sedation and are, therefore, unlikely to be related to increases in plasma F~. These increases in serum urea and creatinine concentrations could be accounted for by the general clinical condition of this group of patients receiving intensive therapy.
Although the results of this study show that, after isoflurane sedation of up to 24 h, metabolism to F" is of insufficient magnitude to cause clinical renal dysfunction, further studies to exclude possible adverse effects of prolonged sedation are warranted.
